Cadila Pharmaceuticals launches Cadalimab™(Adalimumab biosimilar) for India. Adalimumabis a disease-modifying antirheumatic drug and a monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFα) recommended in the treatment of many diseases.
Cadila Pharmaceuticals, one of the leading pharmaceutical companies of India, has recently announced the launch of Adalimumab biosimilar under the brand name Cadalimab™ for the domestic market. Adalimumabis a disease-modifying antirheumatic drug and a monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFα) recommended in the treatment of many diseases.
Adalimumab, popular under the brand name Humira® by Abbvie, is used to treat rheumatoid arthritis, psoriatic arthritis, Ankylosing Spondylitis and psoriasis. In an effort to strengthen their biosimilar product portfolio, Cadalimab™ is the fourth biosimilar launched in the last 2 months by Cadila Pharmaceuticals.
Rheumatoid arthritis :
“Around 7 million* people in India suffer from rheumatoid arthritis, while 0.44-2.8%**of people in India suffer from Psoriasis. While these are not life-threatening, Psoriasis and RA can be painful to live with. With the launch of Cadalimab™, we want to reach these patients with a cost-effective solution and give them a chance at a better life.” shared Amit Ajmera, Vice President, Cadila Pharmaceuticals Limited.
Also Read: MANAGE ARTHRITIS WITH LIFESTYLE CHANGES & STRATEGIES
“With the launch of every product, we strengthen our core philosophy of providing quality medicines to all. Cadalimab™ comes in an easy pre-filled syringe which makes it easy to use for every patient and provides them relief from disorders such as arthritis and Psoriasis. We are on a journey to expand treatment options with affordable biosimilars”, said Mr. O.P. Singh, President -Sales and Marketing, Cadila Pharmaceuticals Limited.
Cadalimab™is available in 40mg/0.8ml injection andhas shown to have significant reduction in signs and symptoms of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis after the usage of Cadalimab™.
Cadila Pharmaceuticals recently launched 3 more biosimilar products in the last 2 months under the name Bevaro™, Ritucad™ and NuPTH for treatment of cancer and osteoporosis. The pharma giant has always been focused on making sure high quality, affordable and life-saving treatments are within the reach of patients. Cadila plans to launch multiple biosimilar products this year for the Indian Market.
Cadila Pharmaceuticals Ltd. (www.cadilapharma.com) is one of the largest privately-held pharmaceutical companies in India. It has recently concluded and cleared USFDA inspection successfully in February 2020. Over the past six decades, Cadila Pharmaceuticals has been engaged in the development and manufacturing of affordable medicines and in making them available for patients across the world. Its innovation-driven drug discovery processes ensure the health and well-being of people around the world.
References-
*https://www.researchgate.net/publication/14889503_Prevalence_of_rheumatoid_arthritis
